Ligand Pharmaceuticals Inc. (LGND)

157.14
NASDAQ : Health Technology
Prev Close 157.14
Day Low/High 0.00 / 0.00
52 Wk Low/High 95.08 / 170.30
Avg Volume 247.80K
Exchange NASDAQ
Shares Outstanding 21.11M
Market Cap 3.22B
EPS -0.10
P/E Ratio 12.15
Div & Yield N.A. (N.A)

Latest News

Ligand Establishes Program To Develop Captisol-Enabled, Next-Generation Contrast Agents For Diagnostic Imaging

Ligand Establishes Program To Develop Captisol-Enabled, Next-Generation Contrast Agents For Diagnostic Imaging

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces initiation of a program to develop contrast agents with reduced renal toxicity.

Ligand Enters Into Worldwide OmniAb® Platform License Agreement With Glenmark Pharmaceuticals

Ligand Enters Into Worldwide OmniAb® Platform License Agreement With Glenmark Pharmaceuticals

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it has entered a worldwide OmniAb platform license agreement with Glenmark Pharmaceuticals.

Ligand Earns $6 Million As OmniAb Partner Out-Licenses Antibody Projects

Ligand Earns $6 Million As OmniAb Partner Out-Licenses Antibody Projects

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that its partner HanAll Biopharma successfully out-licensed antibody projects that were discovered by HanAll using Ligand's OmniAb ® antibody discovery...

Ligand Provides Highlights From Today's Analyst Day Event

Ligand Provides Highlights From Today's Analyst Day Event

At an Analyst Day event held today in New York City, Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) reviewed the recent progress of its business, including its revenue growth opportunities, its portfolio of partnered...

Ligand Reports Third Quarter 2017 Financial Results

Ligand Reports Third Quarter 2017 Financial Results

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and nine months ended September 30, 2017, and provided an operating forecast and program updates.

Reminder: Ligand To Host Analyst Day On November 14th In New York City

Reminder: Ligand To Host Analyst Day On November 14th In New York City

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) will host an Analyst Day on Tuesday, November 14, 2017 from 4:00 p.

Ligand To Participate In The Stephens Fall Investment Conference

Ligand To Participate In The Stephens Fall Investment Conference

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that the company is scheduled to participate in the Stephens Fall Investment Conference in New York City.

Ligand To Report Third Quarter 2017 Results On November 9th

Ligand To Report Third Quarter 2017 Results On November 9th

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today that it plans to report third quarter 2017 financial results after market close on November 9, 2017 and to provide additional commentary during its Analyst...

Ligand To Host Analyst Day On November 14th In New York City

Ligand To Host Analyst Day On November 14th In New York City

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) will host an Analyst Day on Tuesday, November 14, 2017 from 4:00 p.

Ligand Announces Top-Line Results From Phase 2 Study Of LGD-6972 In Patients With Type 2 Diabetes

Ligand Announces Top-Line Results From Phase 2 Study Of LGD-6972 In Patients With Type 2 Diabetes

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced positive top-line results from a Phase 2 clinical study evaluating the efficacy and safety of LGD-6972, as an adjunct to diet and exercise, in subjects...

Ligand To Participate In Two Upcoming Investor Conferences

Ligand To Participate In Two Upcoming Investor Conferences

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that company executives are scheduled to participate in the following upcoming investor conferences: Citi's 12 th Annual Biotech Conference in...

Ligand Appoints Dr. Nancy Gray To Its Board Of Directors

Ligand Appoints Dr. Nancy Gray To Its Board Of Directors

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) ("Ligand" or "the Company") announces the appointment of Nancy Ryan Gray, Ph.

Ligand To Receive $2 Million From WuXi Biologics For Licensing Clinical-Stage Anti-PD-1 Antibody Discovered Using The OmniAb® Technology

Ligand To Receive $2 Million From WuXi Biologics For Licensing Clinical-Stage Anti-PD-1 Antibody Discovered Using The OmniAb® Technology

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) ("Ligand" or "the Company") announces that it will receive a $2 million payment from WuXi Biologics subsequent to their licensing of exclusive rights to the anti-PD-1...

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AAV, ARCC, BID, CFG, ENSG, EXEL, GCAP, HAE, HMLP, LGND, MOMO, MTW, PBR, RYI Downgrades: AEUA, ATSG, ATW, LMNX, MOH, MSB, NBEV, PAGP, SAVE, TIS Initiations: MCRB, TWLO Read on to get TheStreet Quant Ratings' detailed report:

Ligand Reports Second Quarter 2017 Financial Results

Ligand Reports Second Quarter 2017 Financial Results

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and six months ended June 30, 2017, and provided an operating forecast and program updates.

Ligand To Report Second Quarter 2017 Results On August 7th

Ligand To Report Second Quarter 2017 Results On August 7th

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today plans to report second quarter 2017 financial results on August 7, 2017.

Ligand Enters Into Commercial License And Supply Agreement With Amgen For Rights To Use Captisol In The Formulation Of AMG 330

Ligand Enters Into Commercial License And Supply Agreement With Amgen For Rights To Use Captisol In The Formulation Of AMG 330

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that it has entered into a commercial license and supply agreement with Amgen, granting rights to use Ligand's Captisol technology in the formulation of...

Ligand's Partner Melinta Therapeutics Announces U.S. FDA Approval Of Baxdela™ (Delafloxacin) For Acute Bacterial Skin And Skin Structure Infections (ABSSSI)

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that partner Melinta Therapeutics, a privately held company focused on discovering, developing, and commercializing novel antibiotics to treat serious bacterial...

Ligand Enters Into Worldwide OmniAb® Platform License Agreement With Surface Oncology

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it has entered into a worldwide license agreement with Cambridge, Massachusetts-based Surface Oncology.

Ligand Announces Aziyo Biologics Acquires Commercial Products From Partner CorMatrix

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it will receive $10 million from a contractually specified royalty rate buy-down following the sale by CorMatrix Cardiovascular, Inc.

Ligand Enters Into Worldwide OmniAb® Platform License Agreement With XCella Biosciences

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announces it has entered into a worldwide license agreement with Menlo Park, California-based xCella Biosciences, Inc.

Ligand To Participate In Two Upcoming Investor Conferences

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that company executives are scheduled to participate in the following upcoming investor conferences: 14 th Annual Craig-Hallum Institutional...

Ligand Reports First Quarter 2017 Financial Results

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three months ended March 31, 2017, and provided an operating forecast and program updates.

Ligand To Report First Quarter 2017 Results On May 9th

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today plans to report first quarter 2017 financial results on May 9, 2017.

Ligand Enters Commercial License And Supply Agreements With Marinus Pharmaceuticals For Captisol-Enabled Ganaxolone

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that it has entered into commercial License and Supply Agreements (License Agreement) with Marinus Pharmaceuticals, Inc.

Ligand To Participate In Upcoming Investor Conference

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that company executives are scheduled to participate in the following upcoming investor conference: 29 th Annual ROTH Conference in Laguna...

Ligand Provides Highlights From Today's Analyst Day Event

At an Analyst Day event held today in New York City, Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) reviewed the recent progress of its business, its revenue growth opportunities and its portfolio of partnered assets...

TheStreet Quant Rating: B (Buy)